Allozymes puts its accelerated enzymatics to work on a data and AI play, raising $15M

Allozymes, a biotech startup, has raised $15 million in series A funding to expand its business and accelerate its enzyme-screening technique. The company uses a method that allows millions of enzymes to be tested per day, potentially revolutionizing the biotech and chemical industry. Allozymes has already attracted customers across various industries and aims to target 7 billion enzyme variants by 2024.